PLK1 and colorectal carcinoma: In addition, we showed that the inhibition of PLK1 significantly sensitizes CRC cells to oxaliplatin‐based chemotherapy and combination treatment with a PLK1 inhibitor and oxaliplatin exhibits a synergistic effect in CRC in vitro and in vivo.